MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

39.79 3.11

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

38.5

Massimo

40.33

Metriche Chiave
By Trading Economics
Entrata	7.3M -123M
Vendite	3.7M 3.9M
EPS	-1.29
Margine di Profitto	-3,161.261
Dipendenti	594
EBITDA	20M -122M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+124.29% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-542M 3.9B
Apertura precedente	36.68
Chiusura precedente	39.79

Notizie sul Sentiment di mercato

By Acuity

50%

154 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 apr 2026, 23:25 UTC

Principali Notizie su Eventi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 apr 2026, 22:45 UTC

Principali Notizie su Eventi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 apr 2026, 18:03 UTC

Utili

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 apr 2026, 23:58 UTC

Utili

Review & Preview: Earnings Time -- Barrons.com

13 apr 2026, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 apr 2026, 23:33 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 apr 2026, 23:20 UTC

Discorsi di Mercato

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 apr 2026, 23:01 UTC

Utili

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 apr 2026, 23:01 UTC

Utili

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 apr 2026, 23:01 UTC

Utili

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 apr 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 apr 2026, 21:53 UTC

Utili

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 apr 2026, 21:53 UTC

Utili

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 apr 2026, 21:53 UTC

Utili

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 apr 2026, 21:53 UTC

Utili

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 apr 2026, 21:26 UTC

Principali Notizie su Eventi

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 apr 2026, 21:23 UTC

Utili

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 apr 2026, 21:16 UTC

Utili

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 apr 2026, 20:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

13 apr 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

13 apr 2026, 20:34 UTC

Utili

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 apr 2026, 20:34 UTC

Utili

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 apr 2026, 20:34 UTC

Utili

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 apr 2026, 19:59 UTC

Discorsi di Mercato

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 apr 2026, 19:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 apr 2026, 19:27 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Correction to Precious Metals Market Talk on April 9

13 apr 2026, 19:14 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 apr 2026, 18:59 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 apr 2026, 18:59 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 apr 2026, 18:43 UTC

Discorsi di Mercato

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

124.29% in crescita

Previsioni per 12 mesi

Media 86.71 USD 124.29%

Alto 97 USD

Basso 67 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

154 / 348 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.